High-affinity T cell receptors for adoptive cell transfer.
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
02 01 2019
02 01 2019
Historique:
pubmed:
12
12
2018
medline:
31
10
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
Adoptive cell transfer (ACT) of engineered T cell receptors (TCRs) for cancer immunotherapy has evolved from simple gene transfer of isolated TCRs to various affinity enhancement techniques that overcome limitations imposed by central and peripheral tolerance on TCR affinity. In the current issue of the JCI, Poncette et al. used mice with human TCRαβ and HLA gene loci to discover CD4+ TCRs of optimal affinity for cancer testis antigen (CTA) NY-ESO-1. They combined this TCR with a previously discovered NY-ESO-1-specific CD8+ TCR in an ACT fibrosarcoma tumor model to demonstrate the importance of T cell help in mediating antitumor responses.
Identifiants
pubmed: 30530992
pii: 125471
doi: 10.1172/JCI125471
pmc: PMC6307956
doi:
pii:
Substances chimiques
Antigens, Neoplasm
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-71Subventions
Organisme : NIAID NIH HHS
ID : P01 AI072677
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA108835
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA185819
Pays : United States
Organisme : NIBIB NIH HHS
ID : R21 EB023411
Pays : United States
Commentaires et corrections
Type : CommentOn
Références
Nature. 1986 Mar 20-26;320(6059):232-8
pubmed: 2421164
J Immunother. 2014 Apr;37(3):135-46
pubmed: 24598449
ACS Nano. 2015 Jul 28;9(7):6861-71
pubmed: 26171764
Blood. 2007 Jun 15;109(12):5346-54
pubmed: 17327412
Nat Med. 2010 Sep;16(9):1029-34
pubmed: 20693993
J Exp Med. 2017 Nov 6;214(11):3417-3433
pubmed: 28835417
Eur J Immunol. 2003 Dec;33(12):3225-31
pubmed: 14635030
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
J Clin Invest. 2019 Jan 2;129(1):324-335
pubmed: 30530988
Nat Biotechnol. 2005 Mar;23(3):349-54
pubmed: 15723046
Clin Cancer Res. 2010 Dec 1;16(23):5852-61
pubmed: 21138872
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Nature. 2009 Apr 23;458(7241):1043-6
pubmed: 19262510
Blood. 2009 Jul 16;114(3):535-46
pubmed: 19451549
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
J Exp Med. 2010 Oct 25;207(11):2469-77
pubmed: 20921286
Eur J Immunol. 1998 Jan;28(1):193-200
pubmed: 9485199
Nat Biotechnol. 2015 Apr;33(4):402-7
pubmed: 25774714
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Clin Transl Immunology. 2017 Oct 20;6(10):e160
pubmed: 29114389
J Immunol. 2008 May 1;180(9):6116-31
pubmed: 18424733
Nat Immunol. 2003 Jan;4(1):55-62
pubmed: 12469116
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465
N Engl J Med. 2008 Jun 19;358(25):2698-703
pubmed: 18565862